

# PRODUCT INFORMATION




## Pibrentasvir

Item No. 27546

**CAS Registry No.:** 1353900-92-1  
**Formal Name:** N,N'-[[[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)-1-piperidinyl]phenyl]-2,5-pyrrolidinediyl]bis[(6-fluoro-1H-benzimidazole-5,2-diyl)-(2S)-2,1-pyrrolidinediyl][[(1S)-1-[(1R)-1-methoxyethyl]-2-oxo-2,1-ethanediy]]] bis-carbamic acid, dimethyl ester

**MF:** C<sub>57</sub>H<sub>65</sub>F<sub>5</sub>N<sub>10</sub>O<sub>8</sub>  
**FW:** 1,113.2  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 252, 284 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Pibrentasvir is supplied as a crystalline solid. A stock solution may be made by dissolving the pibrentasvir in the solvent of choice, which should be purged with an inert gas. Pibrentasvir is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of pibrentasvir in these solvents is approximately 10, 20, and 25 mg/ml, respectively.

### Description

Pibrentasvir is an inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A).<sup>1</sup> It inhibits HCV replication in stable replicon cell lines containing NS5A from genotypes 1-6 (EC<sub>50</sub>s = 1.4-4.3 pM). Pibrentasvir acts synergistically with the HCV NS3/4A protease inhibitor glecaprevir to inhibit HCV genotype 1b-Con1 replication in replicon cells.<sup>2</sup> Formulations containing pibrentasvir have been used in combination with glecaprevir in the treatment of HCV infection.

### References

1. Wagner, R.R., Randolph, J.T., Patel, S.V., *et al.* Highlights of the structure-activity relationships of benzimidazole linked pyrrolidines leading to the discovery of the hepatitis C virus NS5A inhibitor pibrentasvir (ABT-530). *J. Med. Chem.* **61**(9), 4052-4066 (2018).
2. Ng, T.I., Krishnan, P., Pilot-Matias, T., *et al.* *In vitro* antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. *Antimicrob. Agents Chemother.* **61**(5), e02558-16 (2017).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM